Abstract:
PURPOSE:To produce a nitric acid ester, in high yield and purity, economically in an industrial scale, easily under mild condition, using a regenerable reagent, by reacting a sulfonic acid ester with an organic quaternary ammonium nitrate. CONSTITUTION:The objective compound of formula III can be produced by reacting (A) the sulfonic acid ester of formula II (R'SO2 is sulfonic acid residue) obtained by the conventional sulfonation process of an alcohol of formula I (R is organic residue) with (B) the organic quaternary ammonium nitrate of formula IV(Q is organic quaternary ammonium residue), e.g. a quaternary alkyl (or substituted alkyl) ammonium nitrate or a nitrate of a strongly basic anion exchange resin having quaternary ammonium as an exchangeable group. The process can be applied to a compound which is difficult to be nitrated by conventional methods. When the process is applied to an optically active compound, a nitrate having inverted absolute configuration is prepared without causing racemization.
Abstract:
PROBLEM TO BE SOLVED: To provide a therapeutic and/or prophylactic agent for fatty liver disorder.SOLUTION: A therapeutic and/or prophylactic agent for fatty liver disorder includes a compound having cholesterol ester transfer protein inhibiting activity or its salt or their solvate as an active ingredient.
Abstract:
PROBLEM TO BE SOLVED: To provide a method for efficiently producing optically-active 1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane in a high yield from otpically-active 1-[3,5-bis(trifluoromethyl)phenyl]ethanol while maintaining high optical purity, and further producing an otpically-active material of [3,5-bis(trifluoromethyl)phenyl]ethane derivative.SOLUTION: The method for producing an optically-active material of 1-[3,5-bis(trifluoromethyl)phenyl]ethane derivative includes the step of obtaining optically-active 1-bromo-1-[3,5-bis(trifluoromethyl)phenyl]ethane by brominating optically-active 1-[3,5-bis(trifluoromethyl)phenyl]ethanol by use of, as a brominating agent, (a) a combination of phosphor halide and hydrogen bromide; (b) a combination of 1,2-dibromo-1,1,2,2-tetrachloroethane and an organic phosphor compound represented by general formula (4) P(R)(R)(R) (R, Rand Reach represent 6-10C aryl); or (c) a combination of N-bromosuccinimide and dialkyl sulfide.
Abstract:
PROBLEM TO BE SOLVED: To provide a standard substance for measurement that can be perfectly separated from (R)-2-[3-[N-(benzoxazol-2-yl)-N-[3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid to permit accurate and efficient measurement in the LC/MS/MS method, and to provide its production method. SOLUTION: Deuterated (R)-2-[3-[N-(benzoxazol-d 4 -2-yl)-N-[3-(4-methoxyphenoxy-d 7 )propyl]aminomethyl]phenoxy] butyric acid is useful as a standard substance in mass spectrometric analysis. A manufacturing method of the derivative is also provided. COPYRIGHT: (C)2010,JPO&INPIT
Abstract:
PROBLEM TO BE SOLVED: To provide a compound that shows strong inhibitory action against cholesterol ester transferring protein (CETP), has good oral absorptivity and gives high concentration in blood. SOLUTION: The compound is represented by general formula (I) (wherein X 1 is carbonyl or sulfonyl, X 2 is N atom or C-R 12 , and R 1 , R 2 , R 3 , R 4 and R 5 are each an H atom, a halogen atom, a lower alkyl or the like, R 6 , R 7 , R 8 , and R 12 are each an H atom, a halogen atom, a lower alkyl, or the like, R 9 and R 10 are each an H atom, a lower alkyl, a lower cycloalkyl lower alkyl or the like, and R 11 is an H atom, a halogen atom, a lower alkoxy or the like). COPYRIGHT: (C)2008,JPO&INPIT
Abstract:
NEW MATERIAL:The compound of formula I (R1 is H, lower alkyl, lower alkoxy, etc.; R2 is H or lower alkyl; R3 is nitroxy, trifluoromethyl or F; R4 and R5 are H, lower alkyl, halogen-substituted benzoyl, etc.; A is single bond, O imino, residue of -CONH-, etc.; B is O or residue of -NHCO-; X1 and X2 are aklylene). EXAMPLE:2-Dimethylamino-2'-methoxy-5'-(2-nitroxyethoxy)-acetanilide. USE:Useful as a drug for the circulatory system, e.g. hypotensor, anti-stenocardia, antiarrhythmic agent, etc. PREPARATION:The objective compound of e.g. formula II is produced by using a substituted aniline or a substituted phenol as a starting substance, and reacting e.g. a substituted aniline with a halogeno-aliphatic carboxylic acid or N-protected amino-apliphatic carboxylic acid and its reactive derivative.
Abstract:
PROBLEM TO BE SOLVED: To provide a compound that is useful for producing a medicament for prophylactic or therapeutic treatment of diseases such as dyslipidemia.SOLUTION: There is provided the use of formula (I) for the production of a medicament for prophylactic or therapeutic treatment of dyslipidemia, arteriosclerosis, atherosclerosis, peripheral vascular disease, hyper-LDL-emia, hypo-HDL-emia, hypercholesterolemia, hypertriglyceridemia, familial hypercholesterolemia, cardiovascular disturbance, angina pectoris, ischemia, cardiac ischemia, thrombosis, myocardial infarction, reperfusion disturbance, angioplasty restenosis, or hypertension.
Abstract:
PROBLEM TO BE SOLVED: To provide an agent for treatment and/or prevention of an immune system disease.SOLUTION: The agent for suppressing expression of NFKBIL1, ITGAX, FCER1A, PHACTR1 and/or IRF5 mRNA and the agent for prevention and/or treatment of the immune system disease include a compound with a cholesterol ester transfer protein inhibitory activity or a salt thereof, or a solvate thereof as an active ingredient.
Abstract:
PROBLEM TO BE SOLVED: To provide a substance exhibiting strong inhibiting activity against a cholesterol ester transfer protein (CETP). SOLUTION: The compound is expressed by general formula (I) (R 1 , R 2 , R 3 , R 4 and R 5 are each a hydrogen atom, a halo-lower alkyl, a cyano group or the like; R 6 is an alkyl group, cycloalkyl group or the like; R 7 , R 8 , R 9 and R 10 are each hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group or the like; R 11 and R 12 are each a hydrogen atom, a lower alkyl group, a lower cycloalkyl-lower alkyl group or the like; and R 13 is a hydrogen atom, a halogen atom or the like). COPYRIGHT: (C)2010,JPO&INPIT
Abstract translation:待解决的问题:提供对胆固醇酯转移蛋白(CETP)具有强抑制活性的物质。 解决方案:化合物由通式(I)表示(R 1 SP 1,R 2 SP 2,R SP 3,R SP 3, 4 SP>和R 5 SP>各自为氢原子,卤代低级烷基,氰基等; R 6为烷基,环烷基 或者类似物; R 6,R SP 3,R SP 9,和R 10 SP 10各自为氢原子,卤素 原子,低级烷基,卤代低级烷基等; R 11和R 12分别为氢原子,低级烷基,低级环烷基 - 低级烷基等; R 13是氢原子,卤素原子等)。 版权所有(C)2010,JPO&INPIT